[Skip to Content]

Clinical Trials for Cancer Treatment

Study Title:

EA5142 - Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

What is the purpose of the study?

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.

Upstate Institutional Review Board (IRB) Number:

913688

Study/Protocol ID:

EA5142

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

Where will the study take place?

Upstate Cancer Center-All procedures
Oneida-All procedures
Oswego-All procedures

ClinicalTrials.Gov ID:

NCT02595944

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Erinn Mcdowell, MS, CCRP
Phone: 315-464-8230
Email: mcdowele@upstate.edu

Return to Previous Page || Search Again

Top